In a report released today, Ross Osborn from Cantor Fitzgerald reiterated a Buy rating on Prenetics Group (PRE – Research Report), with a price ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) on January 14 and set a price ...

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) was upgraded by equities research analysts at Cantor Fitzgerald from ...

Fintel reports that on January 13, 2025, Cantor Fitzgerald initiated coverage of Camtek (NasdaqGM:CAMT) with a Neutral ...

Fintel reports that on January 13, 2025, Cantor Fitzgerald initiated coverage of Onto Innovation (NYSE:ONTO) with a ...

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a ...

The Securities and Exchange Commission charged Cantor Fitzgerald with violating laws related to disclosures by so-called blank-check companies before they raise money from the public. Cantor ...

WASHINGTON, Dec 12 (Reuters) - Wall Street brokerage Cantor Fitzgerald has agreed to pay a $6.75 million penalty to settle Securities and Exchange Commission charges that it misled investors in ...

Cantor Fitzgerald Large Cap Focused Fund earns an Above Average Process Pillar rating. The most substantial contributor to the rating is the parent firm's five-year risk-adjusted success ratio of 90%.

Cantor Fitzgerald reiterates an Overweight rating on Avita Medical (RCEL) following the company receiving FDA premarket approval for RECELL GO Mini, its miniaturized device designed to treat ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...

Monday - Cantor Fitzgerald has initiated coverage on Onto Innovation Inc. (NYSE: NYSE:ONTO) shares with an Overweight rating and has set a price target of $250. The new rating is based on the firm ...